Clinical Trials Browser

NCT02393794 2025-10-06

Cisplatin Plus Romidepsin & Nivolumab in Locally Recurrent or Metastatic Triple Negative Breast Cancer (TNBC)

Phase 1/2 Active not recruiting

51 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03426891 2025-10-06

Pembrolizumab and Vorinostat Combined With Temozolomide for Newly Diagnosed Glioblastoma

Phase 1 Completed

21 enrolled 12 charts

CNS

Brain Neoplasms, Glioblastoma

NCT02836548 2025-07-10

HDAC Inhibitor Vorinostat in Resistant BRAF V600 Mutated Advanced Melanoma

Phase 1/2 Completed

33 enrolled

Dermatologic

Melanoma, Skin Neoplasms

NCT02400242 2024-07-09

Study of ACY-241 Alone and in Combination With Pomalidomide and Dexamethasone in Multiple Myeloma

Phase 1 Terminated

85 enrolled

Plasma cell

Multiple Myeloma

NCT01583283 2022-02-23

Study of ACY-1215 in Combination With Lenalidomide, and Dexamethasone in Multiple Myeloma

Phase 1 Completed

38 enrolled

Plasma cell

Multiple Myeloma, Recurrence

NCT00792506 2022-02-02

Phase II Clinical Trial of ITF2357 In Patients With Relapsed/Refractory Multiple Myeloma

Phase 2 Terminated

1 enrolled

Plasma cell

Multiple Myeloma

NCT00792467 2021-05-11

Trial of the Histone-Deacetylase Inhibitor ITF2357 Followed by Mechlorethamine in Relapsed/Refractory Hodgkin's Lymphoma

Phase 1/2 Completed

24 enrolled 13 charts

Lymphoid

Hodgkin Disease

NCT00667082 2017-11-22

NPI-0052 and Vorinostat in Patients With Non-small Cell Lung Cancer, Pancreatic Cancer, Melanoma or Lymphoma

Phase 1 Completed

22 enrolled

DermatologicGastrointestinalLymphoidPlasma cellThoracic

Carcinoma, Non-Small-Cell Lung, Lymphoma, Melanoma, Multiple Myeloma, Pancreatic Neoplasms

NCT01460940 2017-11-14

A Phase II Trial of Panobinostat and Lenalidomide in Patients With Relapsed or Refractory Hodgkin's Lymphoma

Phase 2 Completed

24 enrolled 7 charts

Lymphoid

Hodgkin Disease

NCT00719875 2017-03-03

HDAC Inhibitor Vorinostat (SAHA) With Capecitabine (Xeloda) Using a New Weekly Dose Regimen for Advanced Breast Cancer

Phase 1 Completed

24 enrolled

Breast

Advanced Breast Cancer

NCT01580371 2016-10-06

CKD-581

Phase 1 Completed

39 enrolled

LymphoidPlasma cell

Lymphoma, Multiple Myeloma

NCT00185302 2015-12-14

Safety and Efficacy Study of a New Chemotherapy Agent to Treat Metastatic Melanoma

Phase 2 Completed

28 enrolled

Dermatologic

Melanoma

NCT00738751 2015-02-04

Phase I Study of LBH589 & Erlotinib for Advanced Aerodigestive Tract Cancers

Phase 1 Completed

44 enrolled

Head & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Lung Neoplasms, Neoplasm Metastasis

NCT01090973 2013-12-16

Oral LBH589 in Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) and Mantle Cell Lymphoma (MCL)

Phase 2 Terminated

1 enrolled 6 charts

LymphoidOther hematologic neoplasm

Lymphoma, Non-Hodgkin, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Mantle-Cell

NCT00005624 2012-09-25

CI-994 in Treating Patients With Advanced Myeloma

Phase 2 Completed

6 enrolled

Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

NCT00866762 2011-12-12

A Study of the Efficacy of MK-0683 in Patients With Polycythaemia Vera and Essential Thrombocythaemia

Phase 2 Unknown

60 enrolled

Myeloid

Hematologic Diseases, Polycythemia, Polycythemia Vera, Thrombocythemia, Essential

NCT00697879 2011-11-28

Safety Study of the Histone Deacetylase Inhibitor, CHR-3996, in Patients With Advanced Solid Tumours

Phase 1 Completed

40 enrolled

Tumor-Agnostic

Neoplasms